Global Diabetic Macular Edema Treatment Market 2018-2022

The global diabetic macular edema treatment market is predicted to reach a size of more than USD 4.1 billion by 2022 with the rise in investments on R&D to develop new drugs for diabetic macular edema treatment. Wondering how to make the most of this flourishing industry? Technavio’s extensive industry research report offers a detailed insight that will allow you to take full advantage of the opportunities available to you. This study provides an in-depth analysis of the market by considering the evolving demographics and consumer behavior in the global diabetic macular edema treatment market. It also examines the competitive landscape and some vendors that include Allergan, Alimera Sciences, and Bausch Health.

Check out more insights about the diabetic macular edema treatment industry

Diabetic macular edema treatment market forecast based on regions

Diabetic macular edema treatment industry growth is expected to accelerate over the next five years, driven by increasing R&D in the development of new drugs for diabetic macular edema treatment. The Americas will drive more than 46% of the growth of the diabetic macular edema treatment industry, while EMEA and APAC are also predicted to make noteworthy contributions to the incremental growth in the forecast period. 

Several pharmaceutical companies have increased their spending on R&D to come up with new and more effective drugs for the treatment of diabetic macular edema. The Americas held the largest market share in 2017 followed by EMEA and APAC. However, APAC and EMEA are likely to witness a larger growth during the forecast period than the Americas. Technavio’s diabetic macular edema treatment industry analysis reveals promising markets around the world.

Want a bigger picture? Get a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Diabetic macular edema treatment market drivers

According to the CDC, more than 100 million people are affected with diabetes or prediabetes in the US. Moreover, 1.5 million new cases of diabetes were diagnosed among people aged 18 years and older. As a result, the growing rate of diabetes is causing a higher number of cases of diabetic macular edema. The prevalence of diabetic macular edema is due to the upsurge in the rate of diabetic patients. The major factors behind the growth in incidences of diabetes are the rising prevalence of obesity, hypertension, alcohol consumption, and urbanization. Also, the increasing focus of the leading pharmaceutical companies on finding better and improved drugs is expected to boost the growth of the diabetic macular edema treatment market in the next few years.

Get more value with Technavio’s subscription platform! Gain easy access to all Technavio’s reports, along with on-demand services.      Start your 14-day FREE trial

Diabetic macular edema treatment market vendors

Most of the leading vendors in the global diabetic macular edema treatment market are expected to redesign and replace the existing retinal delivery systems to facilitate improved patient outcomes. The treatment of diabetic macular edema using advanced laser systems provides benefits such as improved precision and security in comparison with standard laser treatment. Many international and regional vendors are vying for their share of the market, and players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several companies, including:

• Allergan
• Alimera Sciences
• Bausch Health
• F. Hoffmann-La Roche
• Regeneron Pharmaceuticals

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements. Get in touch